Chief Pathologist John Cochran discusses how clinical trials offer pathologists the opportunity to work at the forefront of diagnostic discovery in this interview from The Pathologist.

To use next-generation sequencing technology such as RNA-seq for medical and health applications, choosing proper analysis methods for biomarker identification remains a critical challenge for...

Over the past few years, there has been growth in the use of point of care (POC) testing at investigator sites in clinical trials. For example, devices have been deployed at investigator sites to...

The National Cancer Institute conducted the Biospecimen Pre-analytical Variables (BPV) study to determine the effects of formalin fixation and delay to fixation (DTF) on the analysis of nucleic...

Immune cell infiltrates within the tumor microenvironment can influence treatment response and outcome in several cancers. In this study, we developed RNA-based immune signatures from pan-cancer...

Approach to Strategy  

Our CSO Patrice Hugo recently sat with members of The Conference Forum at the Immuno-Oncology 360° 2019 conference, where he discussed immuno-oncology (IO) lab services. He shared the company's...

Authors: Dr. Ayaskant Pany, Sorika Van Niekerk, Johan Venter, Nuria Martinez-Alier, Viola-Marie RaubenheimerIncreased global travel means that infectious disease outbreaks are spreading faster and...

IntroductionHere at the beginning of 2019 it seems fitting to update my personal thoughts on the status of regulated bioanalysis including how we are adapting to the finalized FDA 2018 BMV...

Would you place your full trust in a healthcare provider that kept your medical records in spreadsheets or paper files? Not likely. But every day, one of our most valued business assets –...